Modality
ADC
MOA
GLP-1ag
Target
KIF18A
Pathway
Neuroinflam
PBCRettIPF
Development Pipeline
Preclinical
~Oct 2018
→ ~Jan 2020
Phase 1
Apr 2020
→ Jul 2027
Phase 1Current
NCT07912375
2,441 pts·Rett
2020-04→2027-07·Not yet recruiting
NCT07042970
781 pts·PBC
2025-10→TBD·Completed
3,222 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-07-161.3y awayInterim· Rett
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P1
Not yet…
P1
Complet…
Catalysts
Interim
2027-07-16 · 1.3y away
Rett
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07912375 | Phase 1 | Rett | Not yet recr... | 2441 | SRI-4 |
| NCT07042970 | Phase 1 | PBC | Completed | 781 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| ILM-5680 | Illumina | Phase 2 | BET | |
| NUV-2032 | Nuvalent | Preclinical | KIF18A | |
| CRS-184 | CRISPR Therapeutics | Phase 1/2 | AHR | |
| DNL-9555 | Denali | Phase 1/2 | KIF18A |